American society of clinical oncology statement: Biosimilars in oncology

Gary H. Lyman, Edward Balaban, Michael Diaz, Andrea Ferris, Anne Tsao, Emile Voest, Robin Zon, Michael Francisco, Sybil Green, Shimere Sherwood, R. Donald Harvey, Richard L. Schilsky

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and substitution, (4) value of biosimilars, and (5) prescriber and patient education.

Original languageEnglish (US)
Pages (from-to)1260-1265
Number of pages6
JournalJournal of Clinical Oncology
Volume36
Issue number12
DOIs
StatePublished - Apr 20 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'American society of clinical oncology statement: Biosimilars in oncology'. Together they form a unique fingerprint.

Cite this